Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Go back to Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer| AGENUS (NASDAQ: AGEN) | Delayed: 6.33 -0.18 (2.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.51 | 52 Week High | $7.49 | |||
| Open | $6.36 | 52 Week Low | $2.61 | |||
| Day High | $6.50 | P/E | N/A | |||
| Day Low | $6.16 | EPS | $-1.10 | |||
| Volume | 510,113 | |||||
| (NASDAQ: INKT) | Delayed: 10.71 +0.65 (6.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.06 | 52 Week High | $ | |||
| Open | $10.64 | 52 Week Low | $ | |||
| Day High | $11.68 | P/E | N/A | |||
| Day Low | $10.18 | EPS | $ | |||
| Volume | 29,409 | |||||



